Dr Moncrieff (2003) has suggested that Dr Moncrieff (2003) has suggested that the advantage of clozapine in the advantage of clozapine in treatment-treatmentresistant schizophrenia, when compared resistant schizophrenia, when compared with conventional antipsychotics, may with conventional antipsychotics, may not be substantial. This appears to be not be substantial. This appears to be discordant with an earlier meta-analysis discordant with an earlier meta-analysis (Wahlbeck (Wahlbeck et al et al, 2000) . As clozapine 's , 2000) . As clozapine's advantage in treatment-resistant schizo-advantage in treatment-resistant schizophrenia is well accepted in psychiatry and phrenia is well accepted in psychiatry and is reflected in most practice guidelines, is reflected in most practice guidelines, any questions about its validity need careful any questions about its validity need careful scrutiny. Clues to the disagreement between scrutiny. Clues to the disagreement between meta-analyses on the same topic can often meta-analyses on the same topic can often be found in the studies that are included be found in the studies that are included or excluded, the ways in which the data or excluded, the ways in which the data are abstracted and in the interpretation of are abstracted and in the interpretation of the results (Jadad the results (Jadad et al et al, 1997) . , 1997). Dr Moncrieff included two studies in Dr Moncrieff included two studies in her analysis that were not in the earlier her analysis that were not in the earlier meta-analysis: Essock meta-analysis: Essock et al et al (1996) and Kane (1996) (1996) study was a naturalistic study with serious method-naturalistic study with serious methodological deficiencies from the perspective ological deficiencies from the perspective of determining efficacy of clozapine treat-of determining efficacy of clozapine treatment. The randomisation was imperfect. ment. The randomisation was imperfect. The study was not blinded. The study The study was not blinded. The study population was poorly defined in terms of population was poorly defined in terms of diagnosis. Later application of the Struc-diagnosis. Later application of the Structured Clinical Interview for DSM-III-R tured Clinical Interview for DSM-III-R Personality Disorders to a subgroup of the Personality Disorders to a subgroup of the study population picked up diagnoses study population picked up diagnoses including bipolar disorder, organic mood including bipolar disorder, organic mood disorder and one case of 'no disorder'. disorder and one case of 'no disorder'. 'Crossovers' were allowed, with nearly 'Crossovers' were allowed, with nearly 66% of the control group receiving cloza-66% of the control group receiving clozapine at some time. There was no restriction pine at some time. There was no restriction on the prescription of other medications, on the prescription of other medications, with patients in both groups receiving other with patients in both groups receiving other psychotropic medications, including other psychotropic medications, including other antipsychotics. An intention-to-treat analy-antipsychotics. An intention-to-treat analysis would be meaningless given the number sis would be meaningless given the number of crossovers. Also, analysis of data with of crossovers. Also, analysis of data with crossovers excluded is unlikely to be infor-crossovers excluded is unlikely to be informative as it would end up comparing a mative as it would end up comparing a small subgroup of responders in either small subgroup of responders in either arm of the study. The validity of including arm of the study. The validity of including this study in the meta-analysis is question-this study in the meta-analysis is questionable. This is particularly relevant as the able. This is particularly relevant as the 'forest plot' in Moncrieff's analysis reveals 'forest plot' in Moncrieff's analysis reveals that this is the only study where the effect that this is the only study where the effect size is in the opposite direction (i.e. un-size is in the opposite direction (i.e. unfavourable to clozapine). Thus, inclusion favourable to clozapine). Thus, inclusion of this study would dilute the effect size of of this study would dilute the effect size of clozapine and vice versa. clozapine and vice versa.
Moncrieff's handling of the data from Moncrieff's handling of the data from the Kane the Kane et al et al (2001) study also raises ques-(2001) study also raises questions. In this longer-duration study, patients tions. In this longer-duration study, patients in both the control and experimental groups in both the control and experimental groups were allowed to drop out if they were not were allowed to drop out if they were not responding to the given treatment. A non-responding to the given treatment. A nonintention-to-treat analysis, as Dr Moncrieff intention-to-treat analysis, as Dr Moncrieff has done, would end up comparing a small has done, would end up comparing a small subgroup of responders in either group. An subgroup of responders in either group. An intention-to-treat analysis would have cap-intention-to-treat analysis would have captured clozapine's strength; that is, showing tured clozapine's strength; that is, showing that more patients on clozapine responded that more patients on clozapine responded in comparison with the control group. in comparison with the control group.
Despite these observations, Moncrieff's Despite these observations, Moncrieff's analysis produced an effect size of 0.38 analysis produced an effect size of 0.38 (0.44 using a random effects model). In (0.44 using a random effects model). In my opinion, this is not unimpressive given my opinion, this is not unimpressive given that clozapine is being compared with other that clozapine is being compared with other medications with proven efficacy and not medications with proven efficacy and not placebo. placebo. (2000) on the comparison between (2000) on the comparison between clozapine and conventional antipsychotic clozapine and conventional antipsychotic drugs for treatment-resistant schizophrenia. drugs for treatment-resistant schizophrenia. After selecting nine randomised controlled After selecting nine randomised controlled trials and analysis she concluded that the trials and analysis she concluded that the Cochrane review might have overestimated Cochrane review might have overestimated the effects of clozapine as she found a lower the effects of clozapine as she found a lower overall effect. This was explained by the use overall effect. This was explained by the use of data from intention-to-treat analysis in of data from intention-to-treat analysis in the largest included study by Rosenheck the largest included study by Rosenheck et et al al (1997) and inclusion of the large study (1997) and inclusion of the large study by Essock by Essock et al et al (1996) , which was excluded (1996) , which was excluded in the Cochrane review. in the Cochrane review.
Declaration of interest
There are good reasons for reporting the There are good reasons for reporting the results from the studies by Rosenheck results from the studies by Rosenheck et al et al (1997) and Essock (1997) and Essock et al et al (1996 Essock et al et al ( ) separately (1996 separately from the other seven studies rather than giv-from the other seven studies rather than giving the overall results. These two studies are ing the overall results. These two studies are long-term studies with durations of 1 and 2 long-term studies with durations of 1 and 2 years, respectively. The study populations years, respectively. The study populations were much larger than most of the other were much larger than most of the other studies, which were short-term studies last-studies, which were short-term studies lasting 6-29 weeks. The two long-term studies ing 6-29 weeks. The two long-term studies found a small to no difference in treatment found a small to no difference in treatment effect between clozapine and the conven-effect between clozapine and the conventional antipsychotic. These results have a tional antipsychotic. These results have a large negative impact on the overall effect large negative impact on the overall effect because of the large study populations. because of the large study populations. However, the use of intention-to-treat ana-However, the use of intention-to-treat analysis will result in smaller differences be-lysis will result in smaller differences between the clozapine and control group the tween the clozapine and control group the longer the study lasts, because drop-outs longer the study lasts, because drop-outs are classified as relapses irrespective of the are classified as relapses irrespective of the reason for discontinuation. Longer studies reason for discontinuation. Longer studies tend to have larger drop-out rates, as is also tend to have larger drop-out rates, as is also apparent in this meta-analysis, resulting in apparent in this meta-analysis, resulting in smaller differences between study groups. smaller differences between study groups.
Reporting the results from the short-Reporting the results from the shortterm and long-term studies separately will term and long-term studies separately will probably show that clozapine has a higher probably show that clozapine has a higher treatment effect than that reported by treatment effect than that reported by Moncrieff. Short-term studies explore the Moncrieff. Short-term studies explore the pharmacological efficacy of a medicine pharmacological efficacy of a medicine whereas long-term studies explore the treat-whereas long-term studies explore the treatment effect in daily practice and can be ment effect in daily practice and can be influenced by the patient's willingness to influenced by the patient's willingness to continue treatment. These results should continue treatment. These results should be reported separately. be reported separately. 
